Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anesthetic Dilating Gel (ADG) is a topical ophthalmic combination formulation used primarily for preoperative preparation in cataract surgery and other ocular procedures requiring both pupil dilation (mydriasis) and local anesthesia. The typical formulation contains phenylephrine (a sympathomimetic mydriatic), tropicamide (an antimuscarinic mydriatic), diclofenac (a nonsteroidal anti-inflammatory drug), and lidocaine (an amide-type local anesthetic). The gel achieves rapid and effective pupil dilation while providing corneal anesthesia, with efficacy at least equivalent to traditional regimens using separate drops. Its mechanism of action involves simultaneous blockade of muscarinic receptors in the iris sphincter muscle, stimulation of alpha-adrenergic receptors in the iris dilator muscle, inhibition of prostaglandin synthesis to reduce inflammation, and stabilization of neuronal membranes to prevent pain signal transmission[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anesthetic dilating gel.